Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study.
A double-blind, placebo-controlled crossover study was undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction. Selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels (P < 0.05). This study emphasizes the complex nature of sexual dysfunction in schizophrenic-treated patients and the need for placebo-controlled trials for this condition.
Kodesh
Arad
A
Lev Hasharon Mental Health Medical Center, Pardessiya, Israel.
Weizman
Abraham
A
Aizenberg
Dov
D
Hermesh
Haggai
H
Gelkopf
Marc
M
Zemishlany
Zvi
Z
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011388:Prolactin / Q000097:blood; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use*; D020018:Sexual Dysfunctions, Psychological / Q000097:blood / Q000188:drug therapy*
D014150:Antipsychotic Agents; D012642:Selegiline; D011388:Prolactin